Plasmablastic Lymphoma is a type of lymphoma, which is cancer of the immune system cells. It's made of large cells that look like plasma cells, a type of immune cell. It often affects the mouth area.
Every report comes from a Lived member, sent anonymously.
Have you had Chemotherapy infusion for Plasmablastic Lymphoma?
Plasmablastic lymphoma is a rare, fast-growing cancer of the immune system. It is a type of large B-cell lymphoma, but its cells look and behave much like plasma cells, the mature immune cells that make antibodies. That resemblance shapes which tests confirm it and which treatments work. It often appears in the mouth as a swelling or mass on the gums or jaw that may not hurt, but nearly half of cases start elsewhere, such as the digestive tract, lymph nodes or skin. Fever, night sweats and weight loss are common, and the disease has often spread by the time it is found.
The strongest link is a weakened immune system. Many people with plasmablastic lymphoma have human immunodeficiency virus (HIV), and occasionally the lymphoma is the first sign of it. It also occurs after organ transplants, with long-term immune-suppressing medicines and in older adults. Epstein-Barr virus (EBV), a common virus most people carry harmlessly, is found in the cancer cells in more than half of cases. It can also develop in people with apparently normal immunity, and men are affected more often than women. These are associations: having HIV or EBV does not mean someone will develop it.
Diagnosis requires a biopsy, a piece of the affected tissue examined by a pathologist. Because the cells resemble multiple myeloma and other lymphomas, special stains look for plasma cell markers, signs of EBV and the absence of CD20, a protein found on most B-cell lymphomas. Staging then shows how far it has spread, usually with a PET/CT scan (positron emission tomography combined with computed tomography, which highlights active cancer), blood tests and a bone marrow biopsy. A spinal tap may check the fluid around the brain, particularly for people with HIV, and HIV testing is standard.
The main treatment is combination chemotherapy, several cancer drugs given together in cycles. Specialists often favor regimens more intensive than standard lymphoma chemotherapy, but there is no established standard: the disease is too rare for large trials, and comparisons so far show no clear survival difference. Rituximab, a mainstay for most B-cell lymphomas, rarely helps because it targets CD20. Doctors may instead add bortezomib (Velcade), a multiple myeloma drug; early studies suggest better responses, but none were randomized. For fit people in a first remission, a stem cell transplant using their own stored cells may be offered, and radiation is sometimes added for specific sites. People with HIV take antiretroviral therapy alongside chemotherapy, with the cancer and HIV teams coordinating drug choices.
Chemotherapy typically lasts several months, with frequent blood tests and higher infection risk while blood counts are low. Fatigue, numbness or tingling in the hands and feet, and anxiety can linger afterward, and rehabilitation or counseling can help. The outlook has historically been poor, and nearly half of people either do not respond fully to first treatment or relapse. Recent studies show better results than older reports, especially when the disease is limited to one area. Age over 60 and advanced stage predict worse outcomes, but survival figures come from small studies, so a specialist can best describe an individual outlook. Follow-up usually means exams and blood tests every few months for two years.
See a doctor or dentist about a growing lump or swelling in the mouth or gums, especially if you have HIV or take immune-suppressing medicines. Contact your care team promptly about unexplained fever, drenching night sweats, weight loss or a new lump, since after treatment these can signal a relapse.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Plasmablastic Lymphoma is like, what's helped you, or ask the community a question.